Elin M Svensson

List of Publications by Year
in descending order

58 papers	1,322 citations	331670 21 h-index	395702 33 g-index
60 all docs	60 docs citations	60 times ranked	1058 citing authors

#	Article	IF	Citations
1	Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. Journal of Antimicrobial Chemotherapy, 2015, 70, 1106-1114.	3.0	98
2	Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis. Antimicrobial Agents and Chemotherapy, 2013, 57, 2780-2787.	3.2	85
3	The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis. Clinical Infectious Diseases, 2018, 67, 34-41.	5.8	80
4	A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria. Journal of Antimicrobial Chemotherapy, 2019, 74, 935-943.	3.0	72
5	Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection. Antimicrobial Agents and Chemotherapy, 2014, 58, 6406-6412.	3.2	57
6	Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drugâ€Resistant Tuberculosis: The Effect of Timeâ€Varying Weight and Albumin. CPT: Pharmacometrics and Systems Pharmacology, 2016, 5, 682-691.	2.5	54
7	Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. Journal of Infectious Diseases, 2018, 218, 991-999.	4.0	54
8	Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. Clinical Pharmacokinetics, 2019, 58, 1103-1129.	3.5	50
9	Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials. Clinical Infectious Diseases, 2020, 71, 1817-1823.	5.8	47
10	Modelling of mycobacterial load reveals bedaquilineâ€™s exposureâ€“response relationship in patients with drug-resistant TB. Journal of Antimicrobial Chemotherapy, 2017, 72, 3398-3405.	3.0	46
11	High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clinical Infectious Diseases, 2021, 73, 876-884.	5.8	40
12	Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. Clinical Pharmacokinetics, 2021, 60, 685-710.	3.5	39
13	Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. International Journal of Antimicrobial Agents, 2017, 49, 212-217.	2.5	38
14	Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?. Journal of Antimicrobial Chemotherapy, 2020, 75, 609-617.	3.0	34
15	Clofazimine pharmacokinetics in patients with TB: dosing implications. Journal of Antimicrobial Chemotherapy, 2020, 75, 3269-3277.	3.0	33
16	Increased bactericidal activity but dose-limiting intolerability at 50â€…mgÂ·kg^{â^'1} rifampicin. European Respiratory Journal, 2021, 58, 2000955.	6.7	32
17	Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy. Clinical Pharmacokinetics, 2018, 57, 591-599.	3.5	26
18	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 3237-3246.	3.0	26

#	Article	IF	Citations
19	Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin. Clinical Pharmacokinetics, 2019, 58, 815-826.	3.5	25
20	Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. British Journal of Clinical Pharmacology, 2012, 74, 465-476.	2.4	24
21	Pharmacokinetic Interactions for Drugs with a Long Half-Lifeâ€"Evidence for the Need of Model-Based Analysis. AAPS Journal, 2016, 18, 171-179.	4.4	23
22	Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. British Journal of Clinical Pharmacology, 2018, 84, 2384-2392.	2.4	23
23	Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review. Journal of Antimicrobial Chemotherapy, 2020, 75, 3433-3457.	3.0	23
24	Exposureâ€"safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drugâ€resistant tuberculosis. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1538-1549.	2.5	21
25	Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2018, 22, 26-29.	1.2	17
26	Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1228-1235.	5.6	17
27	Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0268720.	3.2	16
28	Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. Clinical Infectious Diseases, 2022, 75, 141-151.	5.8	16
29	Constructing a representative inâ€silico population for paediatric simulations: Application to HIVâ€positive African children. British Journal of Clinical Pharmacology, 2021, 87, 2847-2854.	2.4	15
30	The pharmacokinetics of paraâ€aminosalicylic acid and its relationship to efficacy and intolerance. British Journal of Clinical Pharmacology, 2020, 86, 2123-2132.	2.4	14
31	Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	13
32	Protein binding of rifampicin is not saturated when using high-dose rifampicin. Journal of Antimicrobial Chemotherapy, 2019, 74, 986-990.	3.0	13
33	Understanding the drug exposureâ€"response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrugâ€resistant tuberculosis. British Journal of Clinical Pharmacology, 2020, 86, 913-922.	2.4	13
34	Rifampicin Can Be Given as Flat-Dosing Instead of Weight-Band Dosing. Clinical Infectious Diseases, 2020, 71, 3055-3060.	5.8	11
35	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	11
36	Population pharmacokinetic drugâ€"drug interaction pooled analysis of existing data for rifabutin and HIV PIs. Journal of Antimicrobial Chemotherapy, 2016, 71, 1330-1340.	3.0	10

#	Article	IF	Citations
37	Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2021, 65, e0239920.	3.2	10
38	Assessing Prolongation of the Corrected QTÂInterval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac SafetyÂof Simplified Dosing Regimens. Clinical Pharmacology and Therapeutics, 2022, 112, 873-881.	4.7	10
39	Pharmacometrics meets statisticsâ€"A synergy for modern drug development. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1134-1149.	2.5	9
40	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. Journal of Infectious Diseases, 2022, 226, 147-156.	4.0	8
41	Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis. Clinical Pharmacokinetics, 2021, 60, 649-654.	3.5	7
42	Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics. Clinical Microbiology and Infection, 2022, 28, 448.e1-448.e7.	6.0	7
43	Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline. Clinical Pharmacokinetics, 2022, 61, 1177-1185.	3.5	7
44	High dose oral rifampicin to improve survival from adult tuberculous meningitis: A randomised placebo-controlled double-blinded phase III trial (the HARVEST study). Wellcome Open Research, 2019, 4, 190.	1.8	6
45	Use of a linearization approximation facilitating stochastic model building. Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41, 153-158.	1.8	5
46	A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis. Clinical Pharmacokinetics, 2021, 60, 943-953.	3.5	5
47	Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease. Chest, 2022, 161, 370-372.	0.8	5
48	The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. Frontiers in Pharmacology, 2021, 12, 637618.	3.5	4
49	Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Journal of Clinical Pharmacology, 2022, 62, 385-396.	2.0	4
50	An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies. Antimicrobial Agents and Chemotherapy, 2021, 65, e0273020.	3.2	3
51	Drug concentration at the site of disease in children with pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy, 2022, 77, 1710-1719.	3.0	3
52	Pharmacometrics in tuberculosis: progress and opportunities. International Journal of Antimicrobial Agents, 2022, 60, 106620.	2.5	3
53	Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens. European Journal of Clinical Pharmacology, 2020, 76, 1557-1565.	1.9	2
54	Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies. European Journal of Clinical Pharmacology, 2021, 77, 727-733.	1.9	2

#	Article	IF	Citations
55	A population pharmacokinetics analysis assessing the exposure of raltegravir onceâ€daily 1200Âmg in pregnant women living with HIV. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 161-172.	2.5	1
56	Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa. Parasites and Vectors, 2021, 14, 524.	2.5	1
57	Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment. Antimicrobial Agents and Chemotherapy, 2022, , AAC0174921.	3.2	1
58	Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis. Expert Review of Clinical Pharmacology, 2022, 15, 161-174.	3.1	1